Evidence map›Paper›PMID 42052748›Full record

Trial reportJournal of comparative effectiveness research2026

Efficacy of selpercatinib as a first-line treatment for

Jessica E Forsyth, Manoj Khanal, Urpo Kiiskinen, Akkula Jyothi, Rajat Goel, Tarun Puri, Shijie Ren, Michael D Sonksen, Xiaofei Wang, Min-Hua Jen

Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of comparative effectiveness research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jessica E ForsythSheffield Centre for Health & Related Research, University of Sheffield, Sheffield, UK.ORCID 0000-0002-5839-9160
Manoj KhanalEli Lilly & Company, Indianapolis, IN 46285, USA.ORCID 0000-0002-3729-3666
Urpo KiiskinenEli Lilly & Company, Indianapolis, IN 46285, USA.ORCID 0000-0003-0791-940X
Akkula JyothiEli Lilly & Company, Indianapolis, IN 46285, USA.
Rajat GoelEli Lilly & Company, Indianapolis, IN 46285, USA.ORCID 0000-0002-8629-6038
Tarun PuriEli Lilly & Company, Indianapolis, IN 46285, USA.ORCID 0000-0003-2399-4362
Shijie RenSheffield Centre for Health & Related Research, University of Sheffield, Sheffield, UK.ORCID 0000-0003-3568-7124
Michael D SonksenEli Lilly & Company, Indianapolis, IN 46285, USA.
Xiaofei WangEli Lilly & Company, Indianapolis, IN 46285, USA.ORCID 0009-0005-6524-6292
Min-Hua JenEli Lilly & Company, Indianapolis, IN 46285, USA.ORCID 0000-0002-4916-0107

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsPyrazolesPyridinesPyrimidinesBayes TheoremHumansProto-Oncogene Proteins c-retAntineoplastic AgentsProto-Oncogene Proteins c-retPyrazolesPyridinesPyrimidinesRET protein, humanselpercatinibBayesian network meta-analysisbiomarkerindirect treatment comparisonnon-small-cell lung cancerpseudo comparator armsingle-arm

Identifiers

PMID42052748
PMCPMC13248994

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.